Stockscreener 앱 받기
227.90
8.61%
18.07
시장 영업 전:
227.00
-0.90
-0.39%
전일 마감가:
$209.83
열려 있는:
$228.09
하루 거래량:
3.76M
Relative Volume:
3.92
시가총액:
$25.07B
수익:
$11.28B
순이익/손실:
$1.07B
주가수익비율:
25.14
EPS:
9.0657
순현금흐름:
$1.33B
1주 성능:
+8.83%
1개월 성능:
+15.58%
6개월 성능:
+25.90%
1년 성능:
+33.68%
1일 변동 폭
$220.00
$237.78
1주일 범위
$204.10
$237.78
52주 변동 폭
$165.78
$237.78
퀘스트 다이아그노스틱스 Stock (DGX) Company Profile
명칭
Quest Diagnostics Inc
전화
(973) 520-2700
주소
500 PLAZA DRIVE, SECAUCUS
Compare DGX vs TMO, DHR, IDXX, A, NTRA
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DGX
Quest Diagnostics Inc
|
227.90 | 25.07B | 11.28B | 1.07B | 1.33B | 9.0657 |
TMO
Thermo Fisher Scientific Inc
|
572.32 | 212.69B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
192.50 | 135.32B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
539.37 | 42.55B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
139.74 | 39.47B | 7.23B | 1.41B | 1.09B | 4.979 |
NTRA
Natera Inc
|
264.69 | 37.91B | 2.50B | -226.32M | 71.51M | -1.6412 |
퀘스트 다이아그노스틱스 Stock (DGX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-30 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2025-08-25 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2025-04-02 | 개시 | Redburn Atlantic | Buy |
| 2025-03-04 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-01-06 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-12-17 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | 재개 | Jefferies | Buy |
| 2024-10-23 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2024-08-28 | 재개 | Evercore ISI | In-line |
| 2024-07-10 | 업그레이드 | Citigroup | Neutral → Buy |
| 2024-02-26 | 개시 | Leerink Partners | Market Perform |
| 2024-02-07 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-01-03 | 개시 | Barclays | Equal Weight |
| 2023-12-12 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-06-29 | 개시 | Piper Sandler | Neutral |
| 2023-05-02 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-04-03 | 업그레이드 | Citigroup | Sell → Neutral |
| 2023-01-23 | 개시 | Evercore ISI | In-line |
| 2022-11-17 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2022-08-22 | 재개 | Morgan Stanley | Equal-Weight |
| 2022-04-04 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-02-23 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-02-02 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-01-28 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2021-05-04 | 업그레이드 | UBS | Neutral → Buy |
| 2021-03-12 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-10-21 | 업그레이드 | Argus | Hold → Buy |
| 2020-07-29 | 업그레이드 | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-07-14 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2020-06-09 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2020-06-02 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2020-04-28 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-27 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-04-27 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2020-03-27 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-08 | 개시 | Wells Fargo | Underweight |
| 2020-01-07 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2019-12-19 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2019-07-15 | 다운그레이드 | Goldman | Neutral → Sell |
| 2019-04-02 | 업그레이드 | Jefferies | Hold → Buy |
| 2019-03-18 | 재개 | Credit Suisse | Neutral |
| 2019-01-31 | 다운그레이드 | Argus | Buy → Hold |
| 2019-01-17 | 개시 | UBS | Neutral |
| 2019-01-03 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2018-12-03 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2018-11-30 | 다운그레이드 | Goldman | Buy → Neutral |
모두보기
퀘스트 다이아그노스틱스 주식(DGX)의 최신 뉴스
Quest Diagnostics stock trades steady as investors weigh recent earnings and diagnostics demand - Ad-hoc-news.de
Trending Industry Today: Quest Diagnostics Leads Gains In CRO Stocks - Moomoo
Quest Diagnostics Incorporated (DGX) Stock Forecasts - Yahoo Finance
Quest Diagnostics Inc (DGX) Shares Surge 8.6% -- What GF Score o - GuruFocus
Quest Continues to Build on Its Hospital Lab Collaborations - Morningstar
Quest Diagnostics Incorporated Stock 12‑Month Price Target Raised to $229.6, Implies 9% Upside - TradingView
Quest Diagnostics Inc (DGX) Q2 2026 Earnings Call Highlights: Strong Revenue Growth Amid ... - Yahoo Finance
Quest Diagnostics Inc (DGX) Q2 2026 Earnings Call Highlights: Strong Revenue Growth Amid Operational Challenges - GuruFocus
Quest Diagnostics Inc. stock outperforms competitors on strong trading day - MarketWatch
Quest Diagnostics 2026: Revenue $3.04B, EPS $2.84— 10-Q Summary - TradingView
Quest Diagnostics (NYSE: DGX) lifts Q2 EPS to $2.84 on 10% revenue growth - Stock Titan
Quest Diagnostics Q2 Earnings Call Highlights - Yahoo Finance
Quest Diagnostics Stock Gains As Oncology Moves Impress Wall Street - StocksToTrade
Quest Diagnostics Stock Hits 52-Week HighHere's WhyQuest Diagnostics (NYSE:DGX) - Benzinga
Quest Diagnostics raises annual forecast on testing demand - Reuters
Quest Diagnostics Q2 2026 Results: Revenue Surges 10%, EPS Up 19%, Full-Year Guidance Raised - Minichart
Quest Diagnostics Announces Q2 2026 Financial Results and Operational Highlights - Kalkine Media
Lockheed Martin, Quest Diagnostics, Thermo Fisher Scientific And Other Big Stocks Moving Higher On Thursday - Benzinga
Tranche Update on Quest Diagnostics Incorporated's Equity Buyback Plan announced on October 20, 2010. - marketscreener.com
Quest Diagnostics stock hits all-time high at 227.31 USD By Investing.com - Investing.com Canada
Transcript: Quest Diagnostics Q2 2026 Earnings Conference Call - Benzinga
DGX Stock Up on Q2 Earnings & Revenue Beat, '26 View Raised - TradingView
Quest Diagnostics Incorporated (DGX) Q2 FY2026 earnings call transcript - Yahoo Finance
Quest’s (NYSE:DGX) Q2 CY2026: Beats On Revenue, Stock Soars - Yahoo Finance
Quest Diagnostics (DGX) Surpasses Q2 Earnings and Revenue Estimates - Yahoo Finance
Quest Diagnostics raises full-year guidance after Q2 revenue rises 10.2% - scanx.trade
Is Quest Diagnostics Inc (DGX) Overvalued After Q2 Earnings Beat - GuruFocus
Quest Diagnostics (NYSE:DGX) Surges After Crushing Q2 Estimates and Raising Guidance - ChartMill
Quest Diagnostics Q2 Adjusted Earnings, Revenue Rise - marketscreener.com
Quest Diagnostics stock rises 5% on strong Q2 beat, raised guidance - Investing.com Canada
(DGX) Quest Diagnostics Expects Full Year 2026 Revenue Range $11.95B$12.05B, vs. FactSet Est of $11.85B - marketscreener.com
Earnings Flash (DGX) Quest Diagnostics Incorporated Reports Q2 Revenue $3.04B, vs. FactSet Est of $2.97B - marketscreener.com
Earnings Flash (DGX) Quest Diagnostics Incorporated Posts Q2 Adjusted EPS $3.12 per Share, vs. FactSet Est of $2.82 - marketscreener.com
Quest Diagnostics (DGX) Earnings Surpass Estimates with Raised FY Adj EPS Forecast - Smartkarma
Quest Diagnostics: Q2 Earnings Snapshot - Yahoo Finance
Quest Diagnostics Reports Second Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026 - PR Newswire
Quest Diagnostics earnings on deck as testing growth accelerates By Investing.com - Investing.com Canada
Quest Diagnostics stock trades steadily as recent earnings and data volumes shape outlook - Ad-hoc-news.de
Global Cancer Biomarkers Market to Reach $37.8 Billion by 2035 as Precision Oncology Adoption Accelerates - GlobeNewswire Inc.
Quest Diagnostics stock trades steadily as investors weigh recent revenue growth and dividend income - Ad-hoc-news.de
Quest Diagnostics Inc. stock underperforms Monday when compared to competitors - MarketWatch
Quest Diagnostics | SCHEDULE 13G/A: Others - Moomoo
Quest Diagnostics stock trades steadily as investors weigh steady revenue and margin trends - Ad-hoc-news.de
Is Quest Diagnostics Inc (DGX) Overvalued After 3.8% Rally? GF V - GuruFocus
A 9-Day Losing Streak Has Quest Diagnostics Stock Down 6.2% - Trefis
Quest Diagnostics stock holds steady as diagnostics demand underpins long term growth - Ad-hoc-news.de
Quest Diagnostics Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Leerink Partners Adjusts Quest Diagnostics Price Target to $244 From $240, Maintains Outperform Rating - marketscreener.com
Quest Diagnostics Currently Down Nine Consecutive Days, on Pace for Longest Losing Streak Since September 2001 -- Data Talk - Moomoo
A4ET8Q Bond Profile — Key Metrics - TradingView
Quest Diagnostics to Report Q2 Earnings: Key Customer Channels in Focus - Zacks Investment Research
퀘스트 다이아그노스틱스 (DGX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.57%
자본화:
|
볼륨(24시간):